Last reviewed · How we verify
Bevacizumab and Capecitabine
Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while capecitabine is a fluoropyrimidine that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.
Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while capecitabine is a fluoropyrimidine that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.
At a glance
| Generic name | Bevacizumab and Capecitabine |
|---|---|
| Sponsor | Central European Cooperative Oncology Group |
| Drug class | Combination therapy: monoclonal antibody (anti-VEGF) and fluoropyrimidine chemotherapy |
| Target | VEGF (bevacizumab); thymidylate synthase (capecitabine) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors depend on for growth and metastasis. Capecitabine is a prodrug that is converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts nucleotide synthesis, leading to cell death. Together, they provide complementary mechanisms: anti-angiogenic therapy combined with cytotoxic chemotherapy.
Approved indications
- Metastatic colorectal cancer
- Metastatic breast cancer
- Gastric cancer
Common side effects
- Hypertension
- Diarrhea
- Hand-foot skin reaction
- Nausea
- Fatigue
- Bleeding/hemorrhage
- Proteinuria
- Neutropenia
Key clinical trials
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- Pan Tumor Rollover Study (PHASE2)
- A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (PHASE2)
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (PHASE1)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: